CLDX — Celldex Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 744218 ·
Last close
$31.49
Market Cap
$2.47B
52W High
$45.14
52W Low
$22.10
ADV30
1,435,544
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 22,000 | — | -80,623,000 | -73,503,000 | 782,349,000 | 47,454,000 | 67,785,000 |
| Mar 2026 | 15,000 | — | -84,435,000 | -78,685,000 | 511,254,000 | 35,729,000 | 55,028,000 |
| Dec 2025 | 121,000 | — | -87,153,000 | -81,317,000 | 582,983,000 | 28,871,000 | 55,818,000 |
| Sep 2025 | 0 | — | -73,617,000 | -67,044,000 | 648,439,000 | 36,037,000 | 50,076,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-222,161,000
Investing CF
$238,241,000
Financing CF
$2,513,000
CapEx
$-4,088,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.26
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,966,169,000
Inventory
—
Receivables
$230,000
ST Investments
$670,133,000
EBIT TTM
$-325,828,000
Pretax Income TTM
$-300,549,000
Interest Exp TTM
—
Analysts
15
Yahoo Snapshot (yfinance, live)
Total Revenue
$158,000
EBITDA
$-322,432,000
Free Cash Flow
$-133,080,496
Enterprise Value
$2,185,056,768
Total Cash
$717,587,008
Total Debt
$4,904,000
Shares Out
78,529,532
Trailing EPS
$-4.35
Book Value
$9.10
ROE
-43.9%
ROA
-27.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,545,000 | -287,367,000 | -258,757,000 | 582,983,000 | 55,818,000 | 527,165,000 | -210,945,000 |
| Dec 2024 | 7,020,000 | -195,078,000 | -157,863,000 | 792,340,000 | 45,335,000 | 747,005,000 | -157,778,000 |
| Dec 2023 | 6,883,000 | -142,042,000 | -141,429,000 | 465,627,000 | 36,456,000 | 429,171,000 | -107,291,000 |
| Dec 2022 | 2,357,000 | -107,096,000 | -112,325,000 | 352,735,000 | 26,531,000 | 326,204,000 | -103,732,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.23
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $35.00 · spot: $31.49 · call volume: 651 · put volume: 148
Expected Move to 2026-12-18:
±$7.85
(24.93%) —
implied range
$23.64 –
$39.34
· ATM straddle on $32.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NEOG | NEOGEN CORP | $2.99B | $13.72 | — |
| ABSI | Absci Corp | $1.63B | $9.49 | — |
| NTLA | Intellia Therapeutics, Inc. | $1.60B | $11.42 | — |
| LNTH | Lantheus Holdings, Inc. | $6.51B | $99.74 | — |
| ACHV | ACHIEVE LIFE SCIENCES, INC. | $797.49M | $7.75 | — |
News headlines (Yahoo Finance, 1h cache)
Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success?
2026-09-23 12:41 · Yahoo
CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’
2026-09-22 17:10 · Yahoo
Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses
2026-09-22 16:02 · Yahoo
Celldex Shares Rise 8% as Barzolvolimab Meets Primary Endpoints in Two Phase 3 Trials
2026-09-22 13:40 · Yahoo
Celldex Therapeutics' Barzolvolimab Meets Phase 3 Endpoints in Two Urticaria Trials
2026-09-22 11:31 · Yahoo
Celldex to Present at Upcoming Investor Conference
2026-09-08 20:01 · Yahoo
Celldex Therapeutics (CLDX) Could Be 130% Undervalued After Second Quarter Results
2026-08-09 06:13 · Yahoo
Celldex Therapeutics (CLDX) Stock Trades At A Premium Despite A 102% Return
2026-08-09 02:08 · Yahoo
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
2026-08-06 23:10 · Yahoo
Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year?
2026-07-24 13:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.